NCT01670799View on ClinicalTrials.gov

Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Interventions
DRUG

Ketorolac

This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.

Trial Locations (1)

87131

University of New Mexico Cancer Center, Albuquerque

All Listed Sponsors
lead

New Mexico Cancer Research Alliance

OTHER

NCT01670799 - Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter